Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

NCT00397189 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

930

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Insomnia

Interventions

DRUG: Circadin
DRUG: placebo circadin

Sponsor

Neurim Pharmaceuticals Ltd.